LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces positive feasibility results in a collaborative study performed by RISE Research Institutes of Sweden. In this Vinnova-funded project, the results showed that Cellevat3d™ microcarriers are highly effective in promoting the growth of HEK293 cells. More importantly, positive feasibility data were obtained for AAV (Adeno-Associated Virus) vector transfection and production, further validating the potential of Cellevat3d™ microcarriers in bioprocessing applications.
“We are excited with the outcomes of this collaboration project with RISE and deeply grateful for the continued financial support from Vinnova. RISE is one of our partners in the validation study program of the Cellevat3d™ microcarriers in bioproduction applications. The positive results from this feasibility study further confirm the potential of this cutting-edge technology in bioprocessing applications and encourage us to continue with the planned studies in cell and gene therapy and novel vaccines production”, says Laura Chirica, CEO Cellevate.
For more information, please contact:
Laura Chirica, PhD
About RISE Research Institutes of Sweden
RISE is an independent, state-owned research institute. As an innovation partner for the entire society, RISE helps develop technologies, products, services, and processes contributing to a sustainable world and competitive industry. RISE does this in collaboration with and on behalf of the academia, private and public sector. RISE also has a particular focus on supporting small and medium-sized companies in their innovation processes. Website: www.ri.se
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.